Loading clinical trials...
Loading clinical trials...
A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Conditions
Interventions
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Decitabine (in combination with BP1002)
Locations
4
United States
Scripps Green Hospital
La Jolla, California, United States
UCLA Medical Center
Los Angeles, California, United States
Weill Cornell Medical College - NewYork-Presbyterian Hospital
New York, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
August 16, 2022
Primary Completion Date
March 1, 2027
Completion Date
September 1, 2027
Last Updated
March 10, 2025
NCT04716452
NCT06459024
NCT06297941
NCT06532084
NCT06125652
NCT05506332
Lead Sponsor
Bio-Path Holdings, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions